Amgen (Nasdaq: AMGN) has reported better-than-expected first quarter 2024 results, with simultaneous news from its obesity pipeline lifting the firm’s stock price by almost 15%.
For the first quarter, total revenues increased 22% to $7.4 billion, with product sales growing 22%, driven by 25% volume growth.
The firm reported a loss per share of $0.21 for the first quarter, down from $5.28 for the first quarter of 2023, driven by a mark-to-market loss on its BeiGene (Nasdaq: BGNE) equity investment and higher operating expenses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze